AJOVista LLC Makes New $84,000 Investment in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)

AJOVista LLC bought a new position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 7,700 shares of the company’s stock, valued at approximately $84,000.

Other large investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. boosted its position in Edgewise Therapeutics by 349.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,338 shares of the company’s stock worth $80,000 after acquiring an additional 5,704 shares during the last quarter. Pale Fire Capital SE purchased a new position in Edgewise Therapeutics during the third quarter worth approximately $90,000. Corton Capital Inc. purchased a new position in shares of Edgewise Therapeutics in the 3rd quarter valued at $98,000. SG Americas Securities LLC purchased a new position in shares of Edgewise Therapeutics in the 3rd quarter valued at $107,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Edgewise Therapeutics by 29.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,833 shares of the company’s stock valued at $228,000 after acquiring an additional 4,785 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Royal Bank of Canada boosted their price objective on Edgewise Therapeutics from $28.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, April 22nd. Piper Sandler initiated coverage on Edgewise Therapeutics in a research note on Thursday, March 7th. They set an “overweight” rating and a $48.00 target price for the company. Wedbush reaffirmed an “outperform” rating and issued a $26.00 price target on shares of Edgewise Therapeutics in a report on Tuesday, April 16th. Finally, Truist Financial reissued a “buy” rating and set a $25.00 price objective on shares of Edgewise Therapeutics in a report on Wednesday, April 17th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Edgewise Therapeutics currently has a consensus rating of “Buy” and an average target price of $31.20.

Insider Buying and Selling at Edgewise Therapeutics

In other news, General Counsel John R. Moore sold 17,993 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $20.00, for a total transaction of $359,860.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CEO Kevin Koch sold 3,152 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $18.91, for a total value of $59,604.32. Following the completion of the sale, the chief executive officer now directly owns 14,478 shares of the company’s stock, valued at approximately $273,778.98. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel John R. Moore sold 17,993 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $20.00, for a total transaction of $359,860.00. The disclosure for this sale can be found here. Insiders have sold 43,287 shares of company stock valued at $852,061 in the last quarter. Corporate insiders own 31.95% of the company’s stock.

Edgewise Therapeutics Price Performance

Shares of NASDAQ:EWTX traded up $0.23 during trading on Friday, reaching $19.52. 545,136 shares of the company’s stock traded hands, compared to its average volume of 586,727. The company has a 50 day moving average of $16.90 and a 200-day moving average of $12.73. Edgewise Therapeutics, Inc. has a 12 month low of $5.12 and a 12 month high of $20.90. The stock has a market capitalization of $1.82 billion, a P/E ratio of -12.35 and a beta of 0.15.

Edgewise Therapeutics (NASDAQ:EWTX) last issued its earnings results on Thursday, February 22nd. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.03). Equities research analysts predict that Edgewise Therapeutics, Inc. will post -1.76 earnings per share for the current fiscal year.

Edgewise Therapeutics Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.